## **Katherine Samaras**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8620953/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The health service contact patterns of people with psychotic and non-psychotic forms of severe mental illness in New South Wales, Australia: A record-linkage study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 675-685.	2.3	3
2	Association between arthritis and cardiovascular risk factors in community-based adults: an opportunity to target cardiovascular risk. BMC Cardiovascular Disorders, 2022, 22, 232.	1.7	3
3	Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701. Diabetes Care, 2021, 44, e74-e74.	8.6	0
4	Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care, 2020, 43, 2691-2701.	8.6	116
5	Comparing the predictive ability of the Edmonton Obesity Staging System with the body mass index for use of health services and pharmacotherapies in Australian adults: A nationally representative crossâ€sectional study. Clinical Obesity, 2020, 10, e12368.	2.0	9
6	Association of Prediabetes and Type 2 Diabetes With Cognitive Function After Stroke. Stroke, 2020, 51, 1640-1646.	2.0	29
7	Mendacity: The Tendency to Lie or Deceive. A Cautionary Tale in Obesity Research, Stigma, and Headlining. Frontiers in Endocrinology, 2020, 11, 598713.	3.5	0
8	Thyroid Peroxidase Antibody Positivity is Associated With Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease. Endocrine Practice, 2020, 26, 1026-1030.	2.1	5
9	A qualitative exploration of barriers and enablers of healthy lifestyle engagement for older Australians with intellectual disabilities. Research and Practice in Intellectual and Developmental Disabilities, 2019, 6, 182-191.	0.1	5
10	The effectiveness of the Keeping the Body in Mind Xtend pilot lifestyle program on dietary intake in first-episode psychosis: Two-year outcomes. Obesity Research and Clinical Practice, 2019, 13, 214-216.	1.8	17
11	Dietary intake of people with severe mental illness: systematic review and meta-analysis. British Journal of Psychiatry, 2019, 214, 251-259.	2.8	160
12	Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. Journal of the American College of Cardiology, 2019, 74, 2554-2568.	2.8	49
13	High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years. Aids, 2018, 32, 451-459.	2.2	27
14	The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Frontiers in Endocrinology, 2018, 9, 705.	3.5	109
15	Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience. Frontiers in Endocrinology, 2018, 9, 634.	3.5	3
16	Body mass index and waist circumference predict health-related quality of life, but not satisfaction with life, in the elderly. Quality of Life Research, 2018, 27, 2653-2665.	3.1	22
17	Solving a weighty problem: Systematic review and meta-analysis of nutrition interventions in severe mental illness. British Journal of Psychiatry, 2017, 210, 110-118.	2.8	153
18	Lifestyle interventions to reduce premature mortality in schizophrenia. Lancet Psychiatry,the, 2017, 4, e14.	7.4	10

KATHERINE SAMARAS

#	Article	IF	CITATIONS
19	Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients. Frontiers in Endocrinology, 2017, 8, 53.	3.5	3
20	Grand Challenge: How Do We Dodge the Obesity Armageddon?. Frontiers in Endocrinology, 2016, 7, 119.	3.5	1
21	Preventing antipsychoticâ€induced weight gain in firstâ€episode psychosis: Transitioning dietitians into routine care. Nutrition and Dietetics, 2016, 73, 303-304.	1.8	3
22	Does statin use cause memory decline in the elderly?. Trends in Cardiovascular Medicine, 2016, 26, 550-565.	4.9	24
23	Metabolic Burden and Disease and Mortality Risk Associated with Impaired Fasting Glucose in Elderly Adults. Journal of the American Geriatrics Society, 2015, 63, 1435-1442.	2.6	7
24	Statinâ€associated myotoxicity in an incarcerated Indigenous youth — the perfect storm. Medical Journal of Australia, 2015, 202, 381-382.	1.7	4
25	Diabetes and Dyslipidemia in Treated Human Immunodeficiency Virus Infection and Approaches for Cardiometabolic Care. , 2015, , 441-469.		Ο
26	Adrenal tumours: how to establish malignancy. BMJ Case Reports, 2014, 2014, bcr2014203736-bcr2014203736.	0.5	3
27	Observation to action: Progressive implementation of lifestyle interventions to improve physical health outcomes in a community-based early psychosis treatment program. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1063-1064.	2.3	5
28	The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney Memory and Ageing Study. Age, 2014, 36, 977-993.	3.0	57
29	The effect of bariatric surgery on serum TRAIL and osteoprotegerin levels in obesity complicated by glucose disorders. E-SPEN Journal, 2014, 9, e210-e214.	0.5	1
30	HIV is an independent predictor of aortic stiffness. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 57.	3.3	30
31	Immune cell-mediated inflammation and the early improvements in glucose metabolism after gastric banding surgery. Diabetologia, 2013, 56, 2564-2572.	6.3	19
32	Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: The role of immune cell activation and insulin resistance. Diabetes and Vascular Disease Research, 2013, 10, 40-48.	2.0	26
33	Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell, 2013, 12, 882-889.	6.7	75
34	Diabetes and the elderly brain: sweet memories?. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 189-196.	3.2	22
35	The Value of the Metabolic Syndrome Concept in Elderly Adults: Is It Worth Less Than the Sum of Its Parts?. Journal of the American Geriatrics Society, 2012, 60, 1734-1741.	2.6	13
36	The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care. Current HIV/AIDS Reports, 2012, 9, 206-217.	3.1	75

KATHERINE SAMARAS

#	Article	IF	CITATIONS
37	The heart of the matter: cardiometabolic care in youth with psychosis. Microbial Biotechnology, 2012, 6, 347-353.	1.7	82
38	Endocrine disease in HIV infection. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, vii-viii.	4.7	9
39	Hair, sweat and tears. BMJ Case Reports, 2011, 2011, bcr0520114177-bcr0520114177.	0.5	4
40	Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. Aids, 2010, 24, 1727-1731.	2.2	17
41	Subcutaneous and Visceral Adipose Tissue FTO Gene Expression and Adiposity, Insulin Action, Glucose Metabolism, and Inflammatory Adipokines in Type 2 Diabetes Mellitus and in Health. Obesity Surgery, 2010, 20, 108-113.	2.1	34
42	Subcutaneous and Visceral Adipose Tissue Gene Expression of Serum Adipokines That Predict Type 2 Diabetes. Obesity, 2010, 18, 884-889.	3.0	219
43	Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study. Dementia and Geriatric Cognitive Disorders, 2010, 30, 569-578.	1.5	107
44	Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism. Current HIV Research, 2009, 7, 456-461.	0.5	9
45	HIV, insulin resistance and cardiovascular disease. Current Cardiovascular Risk Reports, 2009, 3, 59-64.	2.0	Ο
46	Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection. Obesity, 2009, 17, 53-59.	3.0	51
47	Prevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 499-505.	2.1	134
48	How sweet it is? Susceptibility to diabetes mellitus in HIV-1 treatment. HIV Therapy, 2009, 3, 613-624.	0.6	0
49	Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007. 30. 113-119.	8.6	267
50	Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. Journal of Antimicrobial Chemotherapy, 2007, 61, 238-245.	3.0	52
51	Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids, 2007, 21, 2445-2453.	2.2	163
52	Insulin levels in insulin resistance: phantom of the metabolic opera?. Medical Journal of Australia, 2007, 186, 271-272.	1.7	0
53	Insulin levels in insulin resistance: phantom of the metabolic opera?. Medical Journal of Australia, 2006, 185, 159-161.	1.7	32
54	Insulin resistance: More important to identify than quantify (Editorial). Nephrology, 2005, 10, 597-598.	1.6	2

#	Article	IF	CITATIONS
55	In Vivo, Nucleoside Reverseâ€Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA. Journal of Infectious Diseases, 2005, 191, 1686-1696.	4.0	162
56	latrogenic Cushing's Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six Cases. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4394-4398.	3.6	125
57	Obesity Is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences. Circulation, 2004, 109, 3022-3028.	1.6	168
58	No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 363, 429-438.	13.7	241
59	Insulin Resistance, Intra-Abdominal Fat, Cardiovascular Risk Factors, and Androgens in Healthy Young Women with Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1036-1040.	3.6	67
60	Altered Myocellular and Abdominal Fat Partitioning Predict Disturbance in Insulin Action in HIV Protease Inhibitor-Related Lipodystrophy. Diabetes, 2002, 51, 3163-3169.	0.6	119
61	Anti-retroviral therapy, insulin resistance and lipodystrophy. Diabetes, Obesity and Metabolism, 2001, 3, 67-71.	4.4	26
62	Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study. Lancet, The, 1999, 353, 2093-2099.	13.7	1,472
63	Clustering of insulin resistance, total and central abdominal fat: same genes or same environment?. Twin Research and Human Genetics, 1999, 2, 218-225.	1.0	22
64	Genetic and Environmental Influences on Total-Body and Central Abdominal Fat: The Effect of Physical Activity in Female Twins. Annals of Internal Medicine, 1999, 130, 873.	3.9	107
65	Clustering of insulin resistance, total and central abdominal fat: same genes or same environment?. Twin Research and Human Genetics, 1999, 2, 218-225.	1.0	16
66	Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, The, 1998, 351, 1881-1883.	13.7	1,072
67	A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids, 1998, 12, F51-F58.	2.2	2,138